SWard, Author at Break Through Cancer

June 29, 2026June 25, 2026

At a Turning Point for RAS-directed Therapies, Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative

At a Turning Point for RAS-directed Therapies, Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative Backed by a $16M investment, this collaborative effort will help define the next generation of combination therapy strategies for pancreatic cancer News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) June 29, 2026 – At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation today, with support from the Cinelli Family Foundation, announced a $16 million investment in the Conquering KRAS for Patients with Pancreatic Cancer TeamLab. Spanning six world-class cancer research institutions, this......

June 2, 2026

How scientists found a weakness in one of the deadliest ‘undruggable’ cancers | The Washington Post

How scientists found a weakness in one of the deadliest 'undruggable' cancers May 24, 2026 | Calrolyn Johnson “This is the news we've been waiting for. This is the breakthrough — it's been a long time coming,” said Break Through Cancer President Tyler Jacks, PhD, in a recent Washington Post feature examining the decades-long scientific effort that led to KRAS-targeted therapies for pancreatic cancer. In this new article for The Washington Post, Carolyn Johnson traces the scientific journey behind daraxonrasib, from the early discovery of KRAS as a cancer driver to the clinical results that are reshaping expectations for one......

April 21, 2026April 28, 2026

Radical Collaboration: A Cancer Funder Seeks to Solve the Problem of Siloed Research | Inside Philanthropy

Radical Collaboration: A Cancer Funder Seeks to Solve the Problem of Siloed Research April 20, 2026 | Paul Karon Back in 2021, I wrote about Break Through Cancer, then a newly launched organization focused on addressing a literally deadly problem: overly siloed, disconnected research on the second-leading cause of death in the U.S. and worldwide. Beyond funding research, Break Through Cancer’s leaders seek to create a more effective way to build and operate research teams that span multiple specialties, labs and institutions — the better to untangle cancer’s toughest challenges and develop better ways to diagnose and treat patients. While collaboration between......

March 26, 2026

Why some family offices are becoming cancer research’s new bankrollers | Crain Currency

Why some family offices are becoming cancer research's new bankrollers March 13, 2026 | Marcus Baram Family offices are stepping in to fill a widening gap in cancer research funding, deploying billions of dollars of patient capital at a moment when federal cuts threaten to stall laboratories and AI breakthroughs promise to accelerate drug development. Read More at Crain Currency....

March 16, 2026April 21, 2026

𝖡𝗋𝖾𝖺𝗄 𝘛𝘩𝘳𝘰𝘶𝘨𝘩 𝖢𝖺𝗇𝖼𝖾𝗋’𝗌 Tyler Jacks: “We’ve created a new operating model for collaborative cancer research. | The Cancer Letter

Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research. March 13, 2026 | Vol.52 No.10 Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top tier cancer centers. From the start, the foundation’s objective included fostering a change in culture in America’s top labs, ushering in what Jacks calls “radical collaboration” (The Cancer Letter, Feb. 25, 2021). Read More at The Cancer Letter. Watch Tyler's Conversation with Paul here:...

February 24, 2026February 26, 2026

2025 Year in Review: Our Scientific Progress and Clinical Impact

Accelerating Discovery: Break Through Cancer’s 2nd Annual Hackathon Break Through Cancer’s 2025 Year in Review captures a year of measurable scientific progress across our TeamLabs, from advancing multi-site clinical trials to scaling data infrastructure and publishing high-impact research. Together, these efforts reflect the power of radical collaboration™ to drive progress against the deadliest cancers. 📖 Explore the 2025 Year in ReviewJTNDaWZyYW1lJTIwYWxsb3dmdWxsc2NyZWVuJTNEJTIyYWxsb3dmdWxsc2NyZWVuJTIyJTIwYWxsb3clM0QlMjJjbGlwYm9hcmQtd3JpdGUlMjIlMjBzY3JvbGxpbmclM0QlMjJubyUyMiUyMGNsYXNzJTNEJTIyZnAtaWZyYW1lJTIyJTIwc3JjJTNEJTIyaHR0cHMlM0ElMkYlMkZoZXl6aW5lLmNvbSUyRmZsaXAtYm9vayUyRmY4YWIyYzllYzkuaHRtbCUyMiUyMHN0eWxlJTNEJTIyYm9yZGVyJTNBJTIwMXB4JTIwc29saWQlMjBsaWdodGdyYXklM0IlMjB3aWR0aCUzQSUyMDEwMCUyNSUzQiUyMGhlaWdodCUzQSUyMDQwMHB4JTNCJTIyJTNFJTNDJTJGaWZyYW1lJTNF 📖 Watch the 2025 Highlight Video...

February 3, 2026February 4, 2026

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers

New Coalition of Leading Cancer Research Organizations Launched to Accelerate Early Detection of Deadly Cancers $12 million awarded to six collaborative teams developing new approaches to the earlier detection and diagnosis of pancreatic, ovarian, and esophageal cancers News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org New York, NY, February 3, 2026 — The Mark Foundation for Cancer Research today announced the launch of a coalition of leading nonprofit organizations dedicated to solving the critical problem of early detection and diagnosis for some of the world’s deadliest cancers. In partnership with the American Association for Cancer Research (AACR), Lustgarten Foundation,......

December 11, 2025February 10, 2026

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells

Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells A multi-site trial pairs targeted therapy with next-generation MRD testing to track residual disease and uncover vulnerabilities in leukemia cells News Release For Immediate Release Media Contact: Soracha Ward soracha.ward@breakthroughcancer.org (CAMBRIDGE, MASS.) December 11, 2025 – Acute myeloid leukemia (AML) is an aggressive blood cancer, with overall survival remaining approximately 30% at five years despite advances in therapy. Even when patients achieve remission, the disease often returns, fueled by a small number of leukemia cells that survive initial treatment, known as measurable residual disease (MRD). These remaining......

November 26, 2025February 10, 2026

More Than a Patient: How Holly Folgia Turned Her Cancer Journey Into Impact

More Than a Patient: How Holly Folgia Turned Her Cancer Journey Into Impact Holly's journey with stage IV ovarian cancer is one of resilience, creativity, and generosity. As a participant in a Break Through Cancer-funded clinical trial at Memorial Sloan Cancer Center, she is a part of the Targeting Minimal Residual Disease in Ovarian Cancer TeamLab's work to bring new treatment options to patients facing one of the deadliest cancers for women. While undergoing treatment, Holly published a children's book, I Hope You Know, a heartfelt story about the bond between mother and child. She is donating half of the proceeds to ovarian and......

November 21, 2025

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say | The ASCO Post

One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say November 20, 2025 Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery could stop many ovarian cancers from ever developing. Read More at The ASCO Post....